By Marcial Velasco Garrido, Finn Børlum Kristensen, Camilla […]
Comparative Effectiveness Review Methods: Clinical Heterogeneity
This final research report, available in PDF, states that these best practices address critiques from patients, clinicians, policymakers, and others who assert that SRs typically focus on broad populations and, as a result, often lack information relevant to individual patients or patient […]
Comparative Effectiveness: Real-World Evidence of Outcomes
It requires a much broader view of the healthcare system so that information will exist about a patient’s outcome as he or she moves from diagnosis to treatment in the healthcare system. (Source: PharmaVOICE - September 2010) […]
Comparative-Effectiveness Database Debuts
The National Patient Advocate Foundation (NPAF) has created a new Comparative Effectiveness Research (CER) Database available to the public. The new database compiles comparative studies funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The […]
Developing Guidelines To Support Quality Improvement Of Health Economic Publications: PPT Presentation
Quantifying Disease Management Return-on-Investment: Trends, Metrics, Evaluations, Transparency and Reality
This 50-page special report contains insider information from three leading experts in DM analytics. They review key principles in calculating ROI, how to establish metrics for evaluating DM programs, and common mistakes in measuring ROI. They also share some relevant case studies for […]
Health Care Reform: The Uncertain Effectiveness of Comparative Effectiveness Research
Comparative effectiveness research (CER) stands out as the intriguing wild card of health care reform. CER compares competing treatments against each other to determine which interventions work best, supplying critical information for medical decision-making and health policy. If CER works as […]
Comparative Effectiveness Research blog posting in Healthcare Technology News
Healthcare has never been more enmeshed in the political moment. Ever since the announcement of Don Berwick to lead CMS, opposition centered around Berwick's supposed desire to ration care. Berwick's supporters argue that care is already rationed arbitrarily by insurers. […]
Interview – Ulf Staginnus on European Cost-Containment Measures and Effects on Healthcare
Ulf Staginnus, is the creator of HealthEconomics Blog and Head Pricing, Health Economics & Outcome Research, Europe, at Novartis Oncology. He talks about the direct implications of recent European cost-containment measures on the pharmaceutical industry. Watch, and learn why the tough times are […]
Drug pricing facing threat in new NHS order?
Reform for the National Institute for Health and Clinical Excellence and a switch to value-based pricing are on the agenda as the new coalition government lays out its proposals for the National Health Service. (Source: Pharma Times, May 24, 2010) […]
Is The Impact of Comparative Effectiveness Reports Being Evaluated?
It is clear to all informed persons that the nation needs better evidence of what works in health care, and this has propelled comparative effectiveness research (CER) policy developments of late. (Source: Rebecca Singer Cohen, Bryan Luce, Health Affairs Blog, June 30, 2010) […]
Comparative Clinical Effectiveness Research (CCER), Health Information Technology (HIT): Future Developments and Impact on Pharma and Providers
Presentation by Jean Paul Gagnon, PhD, Health Policy Consultant […]
Market access: Risk sharing and alternative pricing schemes
With increasing frequency in Europe, and now starting to show up in the US, biopharma companies and payers are entering into agreements to provide some form of risk sharing or price protection as new drugs are adopted into formularies. (Source: eyeforpharma, August 10, 2010) […]
Comparative Effectiveness Research (CER) and Pharmaceutical Companies (PPT Presentation)
Excellent overview of the use of CER and HEOR […]
MS Risk Sharing failed to deliver results
A pioneering scheme designed by government to impose a money-back guarantee on pharmaceutical companies if their drugs did not adequately treat patients has failed to provide any clear conclusions more than seven years after it was launched. […]
AMCP Format for Formulary Submissions
A Format for Submission of Clinical and Economic Evidence of Pharmaceuticals in Support of Formulary Consideration. FMCP Format Executive Committee. (Source: Journal of Managed Care Pharmacy, Jan. 2010) […]
International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? by Shiroiwa et al.
. […]
Health Plan Considerations for Follow-On Biologics, AMCP Tutorial
YouTube Video where Academy of Managed Care Pharmacy (AMCP) discusses issues that health plans need to consider to prepare for the eventual arrival of follow-on biologics. […]
Health Reform’s CER “Reality Check”
Comparative Effectiveness Research (CER) has been a primary topic of both discussion and legislative debate for the past four Congressional sessions, with both House and Senate resolutions and bills drafted, debated, amended, and ultimately tabled as members tried to arrive at a meaningful way to […]
Market Access EU Presentation, by Janice Haigh
This is a presentation by Janice Haigh at Market Access Europe 2010 that took place March 2-3, 2010. […]
Characteristics of Published Comparative Effectiveness Studies of Medications
Only 32% of medication studies published in top medical journals compared the effectiveness of existing treatments, and active-comparator trials were less likely than trials with inactive controls to report positive results. (Source: Michael Hochman, MD; Danny McCormick, MD, MPH, JAMA, […]
Payer Value Propositions in a More Constricted, Cost-controlled Environment
Xcenda's Managed Markets consultants discuss how manufacturers are revamping their approach to managed care messaging to increase their products' market opportunity. Key points for their presentation include impact of payer environment, building value props throughout the life cycle, and […]
Assessing Comparative Effectiveness Research in the US
by Cohen et al., who support a pluralistic system of CER analyses with a clearinghouse for systematic reviews conducted by multiple evidence-based practice centers, each uniquely suited to its constituency. (Source: Applied Health Economics & Health Policy: December 2009) […]
Is value-based pricing an aid to market access?
Leela Barham explores whether pharma firms can use value-based pricing (VBP) to improve market access. […]
Value-Based Purchasing and Comparative Effectiveness Research
Value-Based Purchasing and Comparative Effectiveness Research: Why the Pharmaceutical, Biotechnology, and Medical-Surgical Device Industries Should Embrace the Coming Market Evolution. (Source: MarCom Group International, Inc.) […]
Guides, Reviews, and Reports from AHRQ
Full list of available quality of care reports, EBM guides, etc. […]
AMCP eDossier System
The AMCP eDossier System is a centralized, secure, web-based platform, that provides qualified health care decision makers the opportunity to easily access, review, and evaluate research to make informed, evidence-based decisions. […]
The impact of value mining on market access
Peter Mansell explains how multiple stakeholders are analyzing data to make their own determinations of medicine value. […]
Comparative Effectiveness Research: Relevance and Applications to Pharmacy
Primer in AJHP by Schumock and Pickard, containing a good basic overview. […]
Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews
Intends to improve the transparency, consistency, and scientific rigor of this work, which consists of systematic reviews of existing research on effectiveness, comparative effectiveness, and comparative harm of different health care interventions. (Source: AHRQ) […]
